After a mean follow‐up of 9.39 (SD = 6.07) years between 1995 and 2021 (median = 7.00 [IQR = 5.00] years until censoring for those lost to follow‐up), 35 (11%) participants were classified with probable dementia (APOE2+, n = 4; APOE3, n = 18; APOE4+, n = 11; missing APOE status, n = 2) and 61 (19%) with cognitive impairment (APOE2+, n = 6; APOE3, n = 29; APOE4+, n = 19; missing APOE status, n = 7), while 267 (81%) remained cognitively unimpaired. The gene discussed is APOE; the disease is Cognitive impairment.